Dan Omstead

Daniel R.
Omstead currently works at abrdn Healthcare Opportunities Fund, as President, Chief Executive Officer & Trustee from 2014, Heading Home, Inc., as Director-Emeritus, HotSpot Therapeutics, Inc., as Director from 2021, abrdn Healthcare Investors, as President & Trustee from 2003, abrdn Life Sciences Investors, as President & Trustee from 2003, abrdn World Healthcare Fund, as President & Trustee from 2015, abrdn, Inc., as Principal, and Tekla Income Edge Fund, as President & Trustee.
Dr. Omstead also formerly worked at Tekla Capital Management LLC, as President & Chief Executive Officer, Reprogenesis, Inc., as President & Chief Executive Officer, Veniti, Inc., as Chairman in 2018, Agilix Corp., as Director, Idun Pharmaceuticals, Inc., as Director, Celladon Corp., as Independent Director from 2013 to 2014, Tibion Corp., as Director from 2011 to 2013, IlluminOss Medical, Inc., as Director from 2011 to 2020, Ebi Life Sciences, Inc., as Director from 2015 to 2017, Neurovance, Inc., as Director from 2015 to 2017, Concentric Medical, Inc., as Director in 2007, Concentric Medical, Inc., as Director from 2008 to 2012, Magellan Diagnostics, Inc., as Director from 2006 to 2016, Elemé Medical, Inc., as Director, CardioKinetix, Inc., as Director, R.W.
Johnson Pharmaceutical Research Institute, as Senior Director, DynexCorp Ltd., as Director from 2012 to 2017, Palyon Medical Corp., as Director from 2009 to 2015, Insightra Medical, Inc., as Director from 2015 to 2016, Euthymics Bioscience, Inc., as Director from 2015 to 2017, Veracyte SD, Inc., as Director from 2016 to 2018, CytoTherapuetics, Inc., as Senior Vice President-Research & Development, Joslin Diabetes Center, Inc., as Trustee from 2016 to 2019, and Ortho Pharmaceutical Corp., as Principal.
Dr. Omstead received his graduate degree and doctorate degree from The Trustees of Columbia University in The City of New York and undergraduate degree from Lehigh University.